RealTime Dynamix™: Rheumatoid Arthritis US & EU Q2 2018 Spotlight

Real time dynamix

Eli Lilly has finally secured FDA approval for the 2mg dose of Olumiant (baricitinib) for the treatment of moderate-to-severe rheumatoid arthritis (RA), and at the same time, positive phase 3 data has been released for AbbVie’s upadacitinib. The below complimentary highlights are taken from the Q2 2018 wave of the quarterly RealTime Dynamix: Rheumatoid Arthritis US series, as well as the Q2 wave of theRealTime Dynamix: Rheumatoid Arthritis EU bi-annual series.

Contact [email protected] for more information about the highlighted reports or to see if your company already has access to the US or EU report series.

Rheumatoid Arthritis

All company, brand or product names and logos in this document are trademarks of their respective holders.